Please provide your email address to receive an email when new articles are posted on . Multidrug-resistant (MDR) gram-negative bacteria continue to present an important threat to public health, and a ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Cefiderocol, a novel siderophore cephalosporin, was noninferior to high-dose meropenem for the ...

Credit: Getty Images. Shionogi has announced positive results from the phase 3 APEKS-NP trial of cefiderocol (S-649266) for the treatment of nosocomial pneumonia. Shionogi has announced positive ...

The US Food and Drug Administration's (FDA's) Antimicrobial Drugs Advisory Committee on Wednesday voted 14–2 to recommend approval of cefiderocol lyophilized powder for intravenous administration for ...

Cefiderocol is also indicated in the U.S. in patients 18 years of age or older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), ...

Acinetobacter baumannii is a bacteria which can become a virulent killer in health-care settings among severely ill patients. The germ has rapidly developed drug resistance to even last-line ...

DUBLIN – The EMA’s Committee for Medicinal Products for Human Use (CHMP) diverged from the FDA on a key decision at its monthly meeting, which concluded Feb. 28. It refused to back an application from ...

Cefiderocol binds to ferric iron and is actively transported into bacterial cells through the outer membrane via the bacterial iron transporters, which function to incorporate this essential nutrient ...

Cefiderocol binds to ferric iron and is actively transported into bacterial cells through the outer membrane via the bacterial iron transporters, which function to incorporate this essential nutrient ...

At its February meeting, the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) recommended two antibacterial agents: cefiderocol and a generic version of ...

Urinary tract infection Study authors discuss the uncertainties and challenges in the interpretation of the CREDIBLE-CR trial and benefit-risk considerations for the use of cefiderocol in clinical ...